schliessen

Filtern

 

Bibliotheken

Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study

Most ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This art... Full description

Journal Title: AIDS care 2010-06-01, Vol.22 (6), p.677-686
Main Author: Malan, Niel
Other Authors: Su, Jun , Mancini, Marco , Yang, Rong , Wirtz, Victoria , Absalon, Judith , McGrath, Donnie , for the CASTLE Study Team
Format: Electronic Article Electronic Article
Language: English
Subjects:
HIV
Quelle: Alma/SFX Local Collection
Publisher: Abingdon: Taylor & Francis Group
ID: ISSN: 0954-0121
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_744699495
title: Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study
format: Article
creator:
  • Malan, Niel
  • Su, Jun
  • Mancini, Marco
  • Yang, Rong
  • Wirtz, Victoria
  • Absalon, Judith
  • McGrath, Donnie
  • for the CASTLE Study Team
subjects:
  • Acquired immune deficiency syndrome
  • Adenine - adverse effects
  • Adenine - analogs & derivatives
  • Adherence
  • Adult
  • Aged
  • AIDS
  • AIDS/HIV
  • Anti-Retroviral Agents - adverse effects
  • Anti-Retroviral Agents - therapeutic use
  • Antiretroviral drugs
  • Antiretroviral therapy
  • Antiretroviral Therapy, Highly Active
  • atazanavir
  • Atazanavir Sulfate
  • Biological and medical sciences
  • Clinical outcomes
  • Deoxycytidine - adverse effects
  • Deoxycytidine - analogs & derivatives
  • Digestive system
  • Drug therapy
  • Drug Therapy, Combination
  • Drug toxicity and drugs side effects treatment
  • Emtricitabine
  • Female
  • Gastrointestinal Diseases - chemically induced
  • GI tolerability
  • Health
  • health-related quality of life
  • HIV
  • HIV Infections - complications
  • HIV Infections - drug therapy
  • HIV-1
  • Human immunodeficiency virus
  • Human viral diseases
  • Humans
  • Immune response system
  • Infectious diseases
  • Irritable bowel syndrome
  • Irritable Bowel Syndrome - chemically induced
  • Lopinavir
  • Male
  • Medical care
  • Medical sciences
  • Medical treatment
  • Medication Adherence
  • Middle Aged
  • Oligopeptides - adverse effects
  • Organophosphonates - adverse effects
  • Pharmacology. Drug treatments
  • Prospective Studies
  • Pyridines - adverse effects
  • Pyrimidinones - adverse effects
  • Quality of Life
  • Ritonavir - adverse effects
  • Surveys and Questionnaires
  • Tenofovir
  • Toxicity: digestive system
  • Viral diseases
  • Viral diseases of the lymphoid tissue and the blood. Aids
  • Young Adult
ispartof: AIDS care, 2010-06-01, Vol.22 (6), p.677-686
description: Most ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naïve HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: "Improvement" (≥2-point positive change from baseline), "No change" (
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0954-0121
fulltext: fulltext
issn:
  • 0954-0121
  • 1360-0451
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.265333
LOCALfalse
PrimoNMBib
record
control
sourceidproquest_cross
recordidTN_cdi_proquest_miscellaneous_744699495
sourceformatXML
sourcesystemPC
sourcerecordid2063003681
originalsourceidFETCH-LOGICAL-c545t-7168eb6c1eabf60d4209a409bea623920b4e6b162f6ea1c181a074aa16548e633
addsrcrecordideNqNks9u1DAQxiMEokvhAbggCwn1FBj_iROjXqpVaSutxIHCNZokjnDltbe2U9gLr9SH4MVwu1uQWqnLyZb9-2a-0XxF8ZrCewoNfABVCaAMFHDOhRT0STGjXEIJoqJPi9nNf5kBule8iPECABhIeF7sMRCyVoLPil8nGFPwxiUdk3FoSfJWB-yMNWlN0A3kcsLbux-JNaMmxuXnZILOuisT0JYOf19faXJ69q2kpXGj7pMeyAqT0S7Fj2TAhGQMfknSd03mR1_OF8ckpmlYvyyejWijfrU994uvn47P56fl4vPJ2fxoUfaVqFJZU9noTvZUYzdKGESeGQWoTqNkXDHohJYdlWyUGmlPG4pQC0QqK9Foyfl-cbCpuwr-csqjtksTe20tOu2n2NYVbwTwqtpNCiGVEup_SFYzlv3vJjlnSqpbn2_vkRd-Cnktsa1A1A00dZMhuoH64GMMemxXwSwxrFsK7U0w2gfByJo328JTt9TDX8VdEjLwbgtg7NGOAV1v4j-OKcbzNJmr7zXvTcqb9i4FNPZRC4cbZU6ID0v84YMd2oRr68NdO_6YvN4pf6Bq08_E_wD0XPU_
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid504780878
display
typearticle
titleGastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study
sourceAlma/SFX Local Collection
creatorMalan, Niel ; Su, Jun ; Mancini, Marco ; Yang, Rong ; Wirtz, Victoria ; Absalon, Judith ; McGrath, Donnie ; for the CASTLE Study Team
creatorcontribMalan, Niel ; Su, Jun ; Mancini, Marco ; Yang, Rong ; Wirtz, Victoria ; Absalon, Judith ; McGrath, Donnie ; for the CASTLE Study Team ; CASTLE Study Team
descriptionMost ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naïve HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: "Improvement" (≥2-point positive change from baseline), "No change" (<2-point change), or "Worsening" (≥2-point negative change). Data were collected on GI adverse events (AEs) and use of GI medications. Of the 599 patients with IBS-QoL-evaluable data through week 24, fewer patients in the ATV/RTV group than in the LPV/RTV group experienced grade 2-4 treatment-related GI AEs including diarrhea (3% versus 10%), nausea (5% versus 7%), and vomiting (<1% on both arms). Nearly three times as many patients receiving LPV/RTV used GI medications. ATV/RTV was associated with an increase in overall IBS-QoL scores and more patients receiving ATV/RTV than LPV/RTV experienced improvement in IBS-QoL through week 24. In contrast to LPV/RTV, ATV/RTV treatment was associated with earlier and more positive improvements in QoL scores across CD4 sub-groups. Differences in the health-related QoL profile between ATV/RTV and LPV/RTV may be important when selecting PI-based antiretroviral regimens.
identifier
0ISSN: 0954-0121
1EISSN: 1360-0451
2DOI: 10.1080/09540120903334641
3PMID: 20467943
4CODEN: AIDCEF
languageeng
publisherAbingdon: Taylor & Francis Group
subjectAcquired immune deficiency syndrome ; Adenine - adverse effects ; Adenine - analogs & derivatives ; Adherence ; Adult ; Aged ; AIDS ; AIDS/HIV ; Anti-Retroviral Agents - adverse effects ; Anti-Retroviral Agents - therapeutic use ; Antiretroviral drugs ; Antiretroviral therapy ; Antiretroviral Therapy, Highly Active ; atazanavir ; Atazanavir Sulfate ; Biological and medical sciences ; Clinical outcomes ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Digestive system ; Drug therapy ; Drug Therapy, Combination ; Drug toxicity and drugs side effects treatment ; Emtricitabine ; Female ; Gastrointestinal Diseases - chemically induced ; GI tolerability ; Health ; health-related quality of life ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV-1 ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Immune response system ; Infectious diseases ; Irritable bowel syndrome ; Irritable Bowel Syndrome - chemically induced ; Lopinavir ; Male ; Medical care ; Medical sciences ; Medical treatment ; Medication Adherence ; Middle Aged ; Oligopeptides - adverse effects ; Organophosphonates - adverse effects ; Pharmacology. Drug treatments ; Prospective Studies ; Pyridines - adverse effects ; Pyrimidinones - adverse effects ; Quality of Life ; Ritonavir - adverse effects ; Surveys and Questionnaires ; Tenofovir ; Toxicity: digestive system ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Young Adult
ispartofAIDS care, 2010-06-01, Vol.22 (6), p.677-686
rights
0Copyright Taylor & Francis Group, LLC 2010
12015 INIST-CNRS
2Copyright Taylor & Francis Ltd. Jun 2010
lds50peer_reviewed
citedbyFETCH-LOGICAL-c545t-7168eb6c1eabf60d4209a409bea623920b4e6b162f6ea1c181a074aa16548e633
citesFETCH-LOGICAL-c545t-7168eb6c1eabf60d4209a409bea623920b4e6b162f6ea1c181a074aa16548e633
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22923225$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20467943$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Malan, Niel
1Su, Jun
2Mancini, Marco
3Yang, Rong
4Wirtz, Victoria
5Absalon, Judith
6McGrath, Donnie
7for the CASTLE Study Team
8CASTLE Study Team
title
0Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study
1AIDS care
addtitleAIDS Care
descriptionMost ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naïve HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: "Improvement" (≥2-point positive change from baseline), "No change" (<2-point change), or "Worsening" (≥2-point negative change). Data were collected on GI adverse events (AEs) and use of GI medications. Of the 599 patients with IBS-QoL-evaluable data through week 24, fewer patients in the ATV/RTV group than in the LPV/RTV group experienced grade 2-4 treatment-related GI AEs including diarrhea (3% versus 10%), nausea (5% versus 7%), and vomiting (<1% on both arms). Nearly three times as many patients receiving LPV/RTV used GI medications. ATV/RTV was associated with an increase in overall IBS-QoL scores and more patients receiving ATV/RTV than LPV/RTV experienced improvement in IBS-QoL through week 24. In contrast to LPV/RTV, ATV/RTV treatment was associated with earlier and more positive improvements in QoL scores across CD4 sub-groups. Differences in the health-related QoL profile between ATV/RTV and LPV/RTV may be important when selecting PI-based antiretroviral regimens.
subject
0Acquired immune deficiency syndrome
1Adenine - adverse effects
2Adenine - analogs & derivatives
3Adherence
4Adult
5Aged
6AIDS
7AIDS/HIV
8Anti-Retroviral Agents - adverse effects
9Anti-Retroviral Agents - therapeutic use
10Antiretroviral drugs
11Antiretroviral therapy
12Antiretroviral Therapy, Highly Active
13atazanavir
14Atazanavir Sulfate
15Biological and medical sciences
16Clinical outcomes
17Deoxycytidine - adverse effects
18Deoxycytidine - analogs & derivatives
19Digestive system
20Drug therapy
21Drug Therapy, Combination
22Drug toxicity and drugs side effects treatment
23Emtricitabine
24Female
25Gastrointestinal Diseases - chemically induced
26GI tolerability
27Health
28health-related quality of life
29HIV
30HIV Infections - complications
31HIV Infections - drug therapy
32HIV-1
33Human immunodeficiency virus
34Human viral diseases
35Humans
36Immune response system
37Infectious diseases
38Irritable bowel syndrome
39Irritable Bowel Syndrome - chemically induced
40Lopinavir
41Male
42Medical care
43Medical sciences
44Medical treatment
45Medication Adherence
46Middle Aged
47Oligopeptides - adverse effects
48Organophosphonates - adverse effects
49Pharmacology. Drug treatments
50Prospective Studies
51Pyridines - adverse effects
52Pyrimidinones - adverse effects
53Quality of Life
54Ritonavir - adverse effects
55Surveys and Questionnaires
56Tenofovir
57Toxicity: digestive system
58Viral diseases
59Viral diseases of the lymphoid tissue and the blood. Aids
60Young Adult
issn
00954-0121
11360-0451
fulltexttrue
rsrctypearticle
creationdate2010
recordtypearticle
recordideNqNks9u1DAQxiMEokvhAbggCwn1FBj_iROjXqpVaSutxIHCNZokjnDltbe2U9gLr9SH4MVwu1uQWqnLyZb9-2a-0XxF8ZrCewoNfABVCaAMFHDOhRT0STGjXEIJoqJPi9nNf5kBule8iPECABhIeF7sMRCyVoLPil8nGFPwxiUdk3FoSfJWB-yMNWlN0A3kcsLbux-JNaMmxuXnZILOuisT0JYOf19faXJ69q2kpXGj7pMeyAqT0S7Fj2TAhGQMfknSd03mR1_OF8ckpmlYvyyejWijfrU994uvn47P56fl4vPJ2fxoUfaVqFJZU9noTvZUYzdKGESeGQWoTqNkXDHohJYdlWyUGmlPG4pQC0QqK9Foyfl-cbCpuwr-csqjtksTe20tOu2n2NYVbwTwqtpNCiGVEup_SFYzlv3vJjlnSqpbn2_vkRd-Cnktsa1A1A00dZMhuoH64GMMemxXwSwxrFsK7U0w2gfByJo328JTt9TDX8VdEjLwbgtg7NGOAV1v4j-OKcbzNJmr7zXvTcqb9i4FNPZRC4cbZU6ID0v84YMd2oRr68NdO_6YvN4pf6Bq08_E_wD0XPU_
startdate20100601
enddate20100601
creator
0Malan, Niel
1Su, Jun
2Mancini, Marco
3Yang, Rong
4Wirtz, Victoria
5Absalon, Judith
6McGrath, Donnie
7for the CASTLE Study Team
general
0Taylor & Francis Group
1Taylor & Francis
2Taylor & Francis Ltd
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
97QJ
107QL
117T2
127T7
137U9
148BJ
158FD
16C1K
17FQK
18FR3
19H94
20JBE
21K9.
22M7N
23P64
247X8
sort
creationdate20100601
titleGastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study
authorMalan, Niel ; Su, Jun ; Mancini, Marco ; Yang, Rong ; Wirtz, Victoria ; Absalon, Judith ; McGrath, Donnie ; for the CASTLE Study Team
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c545t-7168eb6c1eabf60d4209a409bea623920b4e6b162f6ea1c181a074aa16548e633
rsrctypearticles
prefilterarticles
languageeng
creationdate2010
topic
0Acquired immune deficiency syndrome
1Adenine - adverse effects
2Adenine - analogs & derivatives
3Adherence
4Adult
5Aged
6AIDS
7AIDS/HIV
8Anti-Retroviral Agents - adverse effects
9Anti-Retroviral Agents - therapeutic use
10Antiretroviral drugs
11Antiretroviral therapy
12Antiretroviral Therapy, Highly Active
13atazanavir
14Atazanavir Sulfate
15Biological and medical sciences
16Clinical outcomes
17Deoxycytidine - adverse effects
18Deoxycytidine - analogs & derivatives
19Digestive system
20Drug therapy
21Drug Therapy, Combination
22Drug toxicity and drugs side effects treatment
23Emtricitabine
24Female
25Gastrointestinal Diseases - chemically induced
26GI tolerability
27Health
28health-related quality of life
29HIV
30HIV Infections - complications
31HIV Infections - drug therapy
32HIV-1
33Human immunodeficiency virus
34Human viral diseases
35Humans
36Immune response system
37Infectious diseases
38Irritable bowel syndrome
39Irritable Bowel Syndrome - chemically induced
40Lopinavir
41Male
42Medical care
43Medical sciences
44Medical treatment
45Medication Adherence
46Middle Aged
47Oligopeptides - adverse effects
48Organophosphonates - adverse effects
49Pharmacology. Drug treatments
50Prospective Studies
51Pyridines - adverse effects
52Pyrimidinones - adverse effects
53Quality of Life
54Ritonavir - adverse effects
55Surveys and Questionnaires
56Tenofovir
57Toxicity: digestive system
58Viral diseases
59Viral diseases of the lymphoid tissue and the blood. Aids
60Young Adult
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Malan, Niel
1Su, Jun
2Mancini, Marco
3Yang, Rong
4Wirtz, Victoria
5Absalon, Judith
6McGrath, Donnie
7for the CASTLE Study Team
8CASTLE Study Team
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Applied Social Sciences Index & Abstracts (ASSIA)
9Bacteriology Abstracts (Microbiology B)
10Health and Safety Science Abstracts (Full archive)
11Industrial and Applied Microbiology Abstracts (Microbiology A)
12Virology and AIDS Abstracts
13International Bibliography of the Social Sciences (IBSS)
14Technology Research Database
15Environmental Sciences and Pollution Management
16International Bibliography of the Social Sciences
17Engineering Research Database
18AIDS and Cancer Research Abstracts
19International Bibliography of the Social Sciences
20ProQuest Health & Medical Complete (Alumni)
21Algology Mycology and Protozoology Abstracts (Microbiology C)
22Biotechnology and BioEngineering Abstracts
23MEDLINE - Academic
jtitleAIDS care
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Malan, Niel
1Su, Jun
2Mancini, Marco
3Yang, Rong
4Wirtz, Victoria
5Absalon, Judith
6McGrath, Donnie
7for the CASTLE Study Team
aucorpCASTLE Study Team
formatjournal
genrearticle
ristypeJOUR
atitleGastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study
jtitleAIDS care
addtitleAIDS Care
date2010-06-01
risdate2010
volume22
issue6
spage677
epage686
pages677-686
issn0954-0121
eissn1360-0451
codenAIDCEF
abstractMost ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naïve HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: "Improvement" (≥2-point positive change from baseline), "No change" (<2-point change), or "Worsening" (≥2-point negative change). Data were collected on GI adverse events (AEs) and use of GI medications. Of the 599 patients with IBS-QoL-evaluable data through week 24, fewer patients in the ATV/RTV group than in the LPV/RTV group experienced grade 2-4 treatment-related GI AEs including diarrhea (3% versus 10%), nausea (5% versus 7%), and vomiting (<1% on both arms). Nearly three times as many patients receiving LPV/RTV used GI medications. ATV/RTV was associated with an increase in overall IBS-QoL scores and more patients receiving ATV/RTV than LPV/RTV experienced improvement in IBS-QoL through week 24. In contrast to LPV/RTV, ATV/RTV treatment was associated with earlier and more positive improvements in QoL scores across CD4 sub-groups. Differences in the health-related QoL profile between ATV/RTV and LPV/RTV may be important when selecting PI-based antiretroviral regimens.
copAbingdon
pubTaylor & Francis Group
pmid20467943
doi10.1080/09540120903334641